Tag

Professor Sehouli is a gynaecological oncologist, working at the Charité, University of Medicine in Berlin, Germany.

Professor Jalid Sehouli is currently the director of the department of gynecology in the famous Charité/ Campus Virchow-Klinikum and Campus Benjamin Franklin. He is also the head of the European Competence Center for Ovarian Cancer and is leading the gynaecological oncology at all three Campi at Charité Medical University in Berlin.

Professor Sehouli founded the German Foundation for ovarian cancer patients, being involved in many initiatives for patients.

Together with Professor Lichtenegger he founded the German north eastern society for gynaecological oncology (NOGGO). In 2000 he initiated the tumor bank ovarian cancer, which became the largest biobank for fresh frozen tissue worldwide.

Since 2013 Professor Sehouli was nominated as speaker for the OVAR Kommission of the AGO, Germany.

His clinical and scientific interest focuses on the surgical therapy and systemic treatment of advanced gynaecological malignancies. He lead several preclinical trials in predicting the surgical outcome. He is principle investigator in many Phase I to Phase III clinical trials in ovarian cancer.

He has published more than 250 national and international papers in the field of gynaecologic oncology.
He is a member of the executive board of the Arbeitsgemeinschaft Gynäkologische Onkologie (AGO) and the Nord-Ostdeutsche Gesellschaft für Gynäkologische Onkologie (NOGGO), and a member of the European Society of Gynaecological Oncology (ESGO), the Gynaecologic Cancer Intergroup (GCIG), the American Society of Clinical Oncology (ASCO) and the Multinational Association of Supportive Care in Cancer (MASCC).

EUTROC (European Translational Research network in Ovarian Cancer) is a European cancer network addressing the fragmentation currently hindering translational research for cutting edge therapies in ovarian cancer.

It will strengthen European excellence in the diagnosis and treatment of OC.

The need to bring promising drug candidates and treatments into clinical settings is currently delayed by the lack of standardised protocols for preclinical animal studies, lack of suitable ovarian cancer models, lack of validated predictive biomarker diagnostics, and integrated appropriate management of translational research partners (including pharma and biotech companies).

Developing effective diagnostic and treatment strategies require structured joint efforts of experts on tumor immunology, epigenetics, pathology, bioinformatics, drug development and delivery, trial development, clinical oncology and gynecological oncology.

Leading European researchers and clinicians together with the pharmaceutical industry and biotech companies will focus on preclinical and clinical studies in ovarian cancer. Therefore new targets will be identified, validated and translated to new drugs and brought to clinical practice. Standardisation and harmonisation of laboratory practices and good clinical practice procedures will BE performed within the consortium.

The consortium combines expertise in clinical as well as preclinical research. Involved researchers are coordinating a number of investigator-initiated Phase I, II trials.The Network will build a platform for research and strong educational programs for the next generation of experts aimed at developing individualised patients benefit.

Dr Birrer is vice chancellor and director of the Winthrop P. Rockefeller Cancer Institute at the University of Arkansas for Medical Sciences (UAMS).

Birrer completed his medical degree and doctorate of philosophy in 1982 in the Medical Scientist Training Program at the Albert Einstein College of Medicine in New York. Following a medical internship and residency at Massachusetts General Hospital, Birrer entered the Medical Oncology Fellowship program at the National Cancer Institute in Bethesda, Maryland. After his fellowship, Birrer was appointed senior investigator (with tenure) and established the molecular mechanism section in the Division of Cancer Prevention and Control.

In 2008, Birrer was appointed professor of medicine at the Harvard School of Medicine and assumed the position of director for both Gynecologic Medical Oncology at Massachusetts General Hospital and the Gynecologic Oncology Research Program at the Dana Farber/Harvard Cancer Center.

In 2017, he accepted the position of director of the O’Neal Comprehensive Cancer Center at the University of Alabama at Birmingham, where he served as professor of medicine, pathology and OB-GYN.

Recognized nationally and internationally as an expert in gynecologic oncology, Birrer’s primary research interest is in characterizing the genomics of gynecologic cancers to improve the clinical management of these diseases. His clinical interests include ovarian cancer, endometrial cancer and cervical cancer.

Birrer has approximately 400 publications, including peer-reviewed manuscripts, book chapters and review articles. He served as chair and chair emeritus of the Department of Defense Ovarian Cancer Research Program, chair of the Committee for Experimental Medicine of the Gynecologic Oncology Group, chair of the Translational Science Working Group of the Gynecologic Cancer Intergroup, and a member of the Gynecologic Cancer Steering Committee.